These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38648923)

  • 1. Estimating the cost of Rh testing and prophylaxis in early pregnancy: A time-driven activity-based costing study.
    Gilmore EV; Russell LB; Harvie HS; Schreiber CA
    Contraception; 2024 Aug; 136():110468. PubMed ID: 38648923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Rh alloimmunization.
    Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
    J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of foregoing Rh immunoglobulin for bleeding in pregnancy <12 weeks gestation.
    Horvath S; Wang L; Calo W; Yazer MH
    Contraception; 2024 Nov; 139():110530. PubMed ID: 38906503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Rh immune globulin needed in early first-trimester abortion? A review.
    Jabara S; Barnhart KT
    Am J Obstet Gynecol; 2003 Mar; 188(3):623-7. PubMed ID: 12634631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Rh-negative women with first trimester spontaneous abortions need Rh immune globulin?
    Hannafin B; Lovecchio F; Blackburn P
    Am J Emerg Med; 2006 Jul; 24(4):487-9. PubMed ID: 16787810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-D immunoglobulin in RhD prophylaxis.
    Robson SC; Lee D; Urbaniak S
    Br J Obstet Gynaecol; 1998 Feb; 105(2):129-34. PubMed ID: 9501773
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given?
    Bowman JM
    Am J Obstet Gynecol; 1985 Feb; 151(3):289-94. PubMed ID: 2982267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department.
    Weinberg L
    Emerg Med J; 2001 Nov; 18(6):444-7. PubMed ID: 11696491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the management of rh-negative pregnant women.
    Duplantie J; Gonzales OM; Bois A; Nshimyumukiza L; Gekas J; Bujold E; Morin V; Vallée M; Giguère Y; Gagné C; Rousseau F; Reinharz D
    J Obstet Gynaecol Can; 2013 Aug; 35(8):730-740. PubMed ID: 24007709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
    Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
    Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of antenatal prophylaxis.
    Cairns JA
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():19-22. PubMed ID: 9863974
    [No Abstract]   [Full Text] [Related]  

  • 17. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 18. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of indirect antiglobulin screening in Rh(D)-negative women at 28 weeks of gestation.
    Abbey R; Dunsmoor-Su R
    Obstet Gynecol; 2014 May; 123(5):938-945. PubMed ID: 24785843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of Rh D alloimmunization in the first trimester of the pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice].
    Vigoureux S; Maurice P; Sibiude J; Garabedian C; Sananès N
    Gynecol Obstet Fertil Senol; 2024; 52(7-8):446-453. PubMed ID: 38417789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.